United Kingdom Molecular Imaging Market Size, Share, and COVID-19 Impact Analysis, By Modality (Molecular Ultrasound Imaging, Positron Emission Tomography (PET), Single Photon Emission Computed Tomography (SPECT), Nuclear Magnetic Resonance (NMR) Spectrometer, and Others), By Application (Cardiovascular, Neurology, Oncology, Respiratory, and Gastrointestinal), and United Kingdom Molecular Imaging Market Insights, Industry Trend, Forecasts to 2035.

United Kingdom Molecular Imaging Market Insights Forecasts to 2035

• The United Kingdom Molecular Imaging Market Size was estimated at USD 357.23 Million in 2024
• The Market Size is Expected to Grow at a CAGR of around 5.74% from 2025 to 2035
• The United Kingdom Molecular Imaging Market Size is Expected to Reach USD 660.12 Million by 2035

According to a research report published by Spherical Insights & Consulting, the United Kingdom Molecular Imaging Market is anticipated to reach USD 660.12 million by 2035, growing at a CAGR of 5.74% from 2025 to 2035. The rising incidence of chronic illnesses, such as cancer, cardiovascular diseases (CVDs), and neurological disorders, as well as technical developments and increased investment in research and development (R&D), are major factors driving the market's expansion.

Market Overview

The United Kingdom molecular imaging market refers to the section of the healthcare and life sciences sector devoted to the creation, manufacturing, and clinical application of imaging technologies that visualize, describe, and quantify biological processes at the molecular and cellular levels. Many biological activities at the molecular and cellular levels within a living creature can be seen, distinguished, and measured thanks to molecular imaging, a new area of biomedical study. Molecular imaging, as opposed to traditional microscopic biomedical imaging, focuses on certain molecular pathways and mechanisms that are connected to a given disease that occurs within a living organism. It is essential to drug discovery, customized treatment, and early disease identification, especially in fields like cardiology, neurology, and oncology. Growth in the market was driven by government spending on healthcare facilities, such as attractive reimbursement for molecular imaging and therapy. The need for various body scans and tissue injuries is fueled by the aging population and the prevalence of cardiology, neurology, and oncology diseases. These factors have an impact on the molecular imaging industry.

Report Coverage

This research report categorizes the market for the United Kingdom molecular imaging market based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the United Kingdom molecular imaging market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the United Kingdom molecular imaging market.

Driving Factors

The market for United Kingdom molecular imaging is influenced by the market for molecular imaging in the UK is fueled by several factors, including robust academic-industry partnerships, sophisticated healthcare infrastructure, and rising need for accurate and timely disease detection. Innovation in imaging technologies and biomarker discovery is fostered by the nation's top-tier research institutions, especially those in Oxford, Cambridge, and London. The need for more precise diagnostic instruments is being fueled by the rising incidence of chronic illnesses like cancer, neurological disorders, and cardiovascular ailments. Further boosting growth is government assistance through programs like the UK Life Sciences Vision and investments in personalized medicine. The UK is also a desirable location for molecular imaging innovation and commercialization due to its well-established regulatory frameworks and vibrant clinical trial environment.

Restraining Factors

The market growth could be delayed and hampered by the high expenses of imaging systems, radiopharmaceuticals, and specialist infrastructure continue to be significant, stringent regulatory requirements for the approval and handling of radioactive tracers, logistical hurdles, and their short half-life complicates the supply chain.

Market Segmentation

The United Kingdom molecular imaging market share is classified into modality and application.

• The nuclear magnetic resonance (NMR) spectrometer segment accounted for a significant share in 2024 and is anticipated to grow at a rapid pace during the forecast period.

The United Kingdom molecular imaging market is segmented by modality into molecular ultrasound imaging, positron emission tomography (PET), single photon emission computed tomography (SPECT), nuclear magnetic resonance (NMR) spectrometer, and others. Among these, the nuclear magnetic resonance (NMR) spectrometer segment accounted for a significant share in 2024 and is anticipated to grow at a rapid pace during the forecast period. Clinical diagnostics is now one of the areas where NMR technology is being used outside of typical research settings due to advancements in sensitivity, resolution, and data collecting speed. NMR spectroscopy is even more useful in precision medicine and individualized healthcare since it can produce large, multidimensional data sets.

• The oncology segment held the largest market share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The United Kingdom molecular imaging market is segmented by application into cardiovascular, neurology, oncology, respiratory, and gastrointestinal. Among these, the oncology segment held the largest market share in 2024 and is expected to grow at a significant CAGR during the forecast period. This is because of the increasing incidence of cancer and the increased need for sophisticated diagnostic tools. Technologies for molecular imaging offer vital insights into the biology of tumors, facilitating precise staging, early identification, and efficient treatment response tracking. Clinical decision-making is enhanced by the precise visualization of tumor metabolism and structure made possible by tools like PET/CT and SPECT/CT.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the United Kingdom molecular imaging market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Blue Earth Diagnostics
• Perspectum
• IXICO plc
• Brainomix
• Edinburgh Molecular Imaging
• Cirdan Ltd
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at United Kingdom, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the United Kingdom molecular imaging market based on the below-mentioned segments:

United Kingdom Molecular Imaging Market, By Modality

• Molecular Ultrasound Imaging
• Positron Emission Tomography (PET)
• Single Photon Emission Computed Tomography (SPECT)
• Nuclear Magnetic Resonance (NMR) Spectrometer
• Others

United Kingdom Molecular Imaging Market, By Application

• Cardiovascular
• Neurology
• Oncology
• Respiratory
• Gastrointestinal